Diopter Technologies

What Diopter Technologies does

Diopter Technologies is a privately held, clinical-stage medical device company founded in 2018 and headquartered in Boston, Massachusetts. The company develops bio-integrated therapeutic contact lenses that combine drug-delivering polymer platforms with amniotic membrane-derived biomaterials to treat ocular surface diseases including dry eye syndrome, corneal trauma injuries, post-surgical wounds, and chemical or thermal injuries.

Its core technology centers on two platform architectures: drug-loaded polymer matrices embedded in contact lens material that release controlled doses of medication (e.g., moxifloxacin) over time, and self-dissolving biopolymer contact lenses made from amniotic membrane material that release growth factors and anti-inflammatory proteins over a 48-72 hour wear period before fully dissolving. The lead product is the Dissolving Amniotic Membrane Biopolymer Contact Lens, with three additional pipeline candidates: Bio2020 (dual layer amnion and bioresorbable polymer for corneal wounds), Cat3560 (triple drug combination releasing lens for post-cataract surgery), and Mox5050 (moxifloxacin-releasing lens branded Glint Lens).

The company operates on a planned B2B medical device sales model targeting ophthalmologists, eye clinics, and healthcare systems via direct engagement, currently relying on industry conference participation and press releases ahead of commercial launch. Revenue generation is contingent on FDA 510(k) clearance with Q1 2026 targeted for product launch, after which the company intends to use existing reimbursement codes. The company is pre-revenue, holds multiple patents covering biomimetic drug-eluting platforms, and reports 1-10 employees led by CEO Chris Adams (former commercialization lead for a corneal wound healing contact lens that treated over 1,000,000 patients).

Name

Diopter Technologies

Legal name

Diopter Technologies

Website

https://diopterlabs.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Diopter Technologies is a clinical-stage medical device company developing drug-delivering and amnion-based dissolvable contact lenses for treating ocular surface diseases, including dry eye syndrome, corneal injuries, and post-surgical wounds. The company targets ophthalmologists and eye care providers ahead of its planned Q1 2026 commercial launch following FDA 510(k) clearance.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAHAIAL

Ocular Drug Delivery Devices (Eye Droppers/Inserts)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

SECONDARYHLAHAJAE

Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

SECONDARYHLAHANAG

Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables

Keywords

• Therapeutic contact lenses
• Ophthalmic medical devices
• Drug delivery lenses
• Amniotic membrane products
• Ocular surface treatments

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. Medical Device Sales - Therapeutic Contact Lenses: Sale of drug-delivering and amnion-based dissolvable contact lenses to healthcare providers and patients. The company plans to launch the product in Q1 2026 following FDA 510(k) clearance. Uses existing reimbursement codes for the technology.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Diopter Technologies develops and manufactures therapeutic contact lenses for treating ocular surface diseases. Its core product is a dissolving amniotic membrane biopolymer contact lens designed to deliver therapeutic benefits to the ocular surface. The company is also developing drug-delivering contact lens technology and is pursuing FDA 510(k) clearance with a planned Q1 2026 commercial launch.

Product overview

Diopter Technologies offers a portfolio of drug-delivering and amnion-based dissolvable contact lens products for treating ocular surface diseases. The core technology platform includes drug-delivering contact lenses that embed medication releasing controlled doses directly to the eye, and amnion-based dissolvable lenses that utilize natural healing properties of amniotic membrane. Key products include the Dissolving Amniotic Membrane Biopolymer Contact Lens (primary clinical-stage device), Bioshare Polymer Amniotic Membrane Dissolving Device, and three products in development: Bio2020 for corneal wounds, Cat3560 for post-cataract surgery, and Mox5050 for corneal infections. The company is preparing for Q1 2026 commercial launch following FDA 510K submission.

Differentiator

Problem solved

Functional benefit

Products and services

• Dissolving Amniotic Membrane Biopolymer Contact Lens A proprietary biopolymer contact lens that dissolves on the ocular surface to deliver amniotic membrane-derived regenerative therapy, designed for ophthalmologists and optometrists treating ocular surface diseases.
• Drug-Delivering Contact Lens A therapeutic contact lens technology platform designed to deliver pharmaceutical agents to the ocular surface, intended for eye care providers treating ocular surface conditions.

Quantifiable outcome

• Dissolves completely within 48-72 hours, avoiding removal procedures
• +4 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• EyePoint Pharmaceuticals: Specializes in sustained-release ocular drug delivery using bioerodible implants (Durasert platform) for retinal and other eye diseases. Comparable to Diopter as a focused ocular drug-delivery company expanding therapeutic reach across multiple ophthalmic indications.
• Glaukos Corporation: Specialty ophthalmic medical technology company focused on interventional therapies for glaucoma and corneal disorders, including drug-delivery approaches. Comparable to Diopter in targeting ophthalmic disease with combined device/therapeutic strategies.
• Novaliq: Develops water-free topical ocular therapeutics (EyeSol platform) for dry eye and other ocular surface diseases. Comparable to Diopter as a company attacking ocular surface disease with novel non-traditional drug-delivery technology.
• Ocular Therapeutix: Commercial-stage company developing drug-eluting intracanalicular inserts and ocular implants for post-surgical pain, inflammation, and other ocular conditions. Most directly comparable to Diopter as another ocular drug-delivery platform targeting ophthalmology indications.

Broad incumbents

• Alcon: Largest global ophthalmic medical device and pharmaceutical company with surgical, vision care, and pharmaceuticals businesses including contact lenses. Comparable as the dominant incumbent that Diopter will need to engage with across ophthalmology sales channels.
• Bausch + Lomb: Major ophthalmic company with a leading contact lens franchise (including therapeutic lenses) and broad pharmaceuticals and surgical portfolios. Comparable as an incumbent with both contact lens manufacturing capabilities and the commercial scale to compete in ocular therapeutics.
• Johnson & Johnson Vision: Division of Johnson & Johnson that markets the Acuvue contact lens family and other ophthalmic surgical products. Comparable as a large incumbent with deep contact-lens manufacturing, R&D, and global commercial reach in eye care.

Emerging players

• SightGlass Vision: Developer of therapeutic spectacle and contact lenses (Diffusion Optics Technology) targeting myopia progression in children. Comparable as a company using lens-based modalities to deliver therapeutic effects to the eye, addressing underserved ophthalmology indications.
• Kala Bio: Clinical-stage ophthalmic company using mucus-penetrating particle technology to enhance drug delivery to ocular tissues. Comparable as an emerging ophthalmic drug-delivery developer pursuing improved bioavailability in eye therapeutics.
• Nicox: European ophthalmic R&D company developing therapeutics leveraging nitric oxide and other unique mechanisms for glaucoma and ocular surface disease. Comparable as a specialty ophthalmic therapeutics developer competing for the same physician prescriber base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/diopter-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diopter Technologies